SCHEMBL26608487

SCHEMBL26608487

CCOC(=O)c1c(C)nc(Cl)c(N(C)C)c1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.46
KDM4E B2RXH2 3/20 0.46
LMNA P02545 3/20 0.46
NPC1 O15118 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
HSP90AA1 P07900 1/20 0.44
ADORA3 P0DMS8 5/20 0.44
TP53 P04637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PDE4D Q08499 1/20 0.41
PDE4B Q07343 1/20 0.41
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31336300 1.00 RAB9A (0.46) RAB9AKDM4ELMNANPC1SMN1; SMN2
SCHEMBL26608329 0.87 RAB9A (0.51) RAB9AKDM4ELMNANPC1SMN1; SMN2
SCHEMBL31336276 0.87 RAB9A (0.51) RAB9AKDM4ELMNANPC1SMN1; SMN2
SCHEMBL31336249 0.86 ADORA3 (0.50) RAB9AKDM4ELMNANPC1SMN1; SMN2
SCHEMBL26608268 0.86 ADORA3 (0.50) RAB9AKDM4ELMNANPC1SMN1; SMN2
SCHEMBL31336263 0.82 KMT2A (0.48) RAB9AKDM4ELMNANPC1SMN1; SMN2
SCHEMBL26608464 0.82 KMT2A (0.48) RAB9AKDM4ELMNANPC1SMN1; SMN2
SCHEMBL31336221 0.81 KMT2A (0.47) RAB9AKDM4ELMNANPC1SMN1; SMN2
SCHEMBL26601732 0.81 KMT2A (0.47) RAB9AKDM4ELMNANPC1SMN1; SMN2
SCHEMBL30593200 0.81 KMT2A (0.47) RAB9AKDM4ELMNANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 US disclosed
EP-4511115-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
WO-2023205468-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
WO-2023205468-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN8A, SCN1B, SCN3A RAB9A 1794/4885KDM4E 4442/4885LMNA 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.